Michele V. McNeill, Pharm.D.
Joined the amfAR board in December 1996. Expertise in management of process
for drug testing and approval. Was instrumental in establishing the Paul Corser AIDS
Research Opportunity Fund, pledging $2 for every dollar, up to $100,000, contributed by
amfAR donors. The Opportunity Fund supports projects that fall outside amfAR’s targeted
research initiatives or regular grant cycles.
Dr. McNeill is founder and former chief executive officer of Kern
McNeill International (KMI), a contract research organization providing
clinical drug development services to research-based pharmaceutical
manufacturers. At KMI, she pioneered work to provide access to
investigational drugs for serious, life-threatening illnesses, such as
AIDS and cancer. More than 80,000 patients received treatment from
programs managed by KMI prior to its acquisition several years ago by
United Healthcare, Inc.
Earlier, Dr. McNeill practiced clinical pharmacy at Thomas Jefferson
University Hospital in Philadelphia, PA, and at Erie County Medical
Center in Buffalo, NY. She launched her career in the pharmaceutical
industry at Warner Lambert and went on to hold key management
positions at Hoffmann-La Roche and Ciba-Geigy (now Novartis). Currently, Dr. McNeill
serves on the Therapeutic and Research Working Group in the Office of AIDS Research
at the National Institutes of Health.
She and her husband, Doug, live in Longboat Key, FL.